• Viatris Inc. recently received U.S. Food and Drug Administration approval for Gwyn Lo, a once-weekly low-estrogen combined hormonal contraceptive patch for women with a body mass index below 30 kg/m², supported by Phase 3 data showing contraceptive efficacy, a well-characterized safety profile and strong patch adhesion.
• By adding a low-dose, non-invasive, weekly contraceptive option that targets women seeking convenience and reversibility, Viatris is broadening its branded and complex product mix beyond traditional oral therapies.
• We’ll now examine how the FDA approval of Gwyn Lo could reshape Viatris’ investment narrative around higher-margin, innovative product growth.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Viatris Investment Narrative Recap

To own Viatris, you need to believe the company can gradually shift from a pressured generics base to a more resilient mix of complex and branded products, while managing its debt load and uneven profitability. The FDA approval of Gwyn Lo fits that story by adding a branded, potentially higher-margin contraceptive, but it does not by itself resolve core risks around pricing pressure in generics, regulatory scrutiny and the need to keep new product launches coming.

The most relevant recent announcement alongside Gwyn Lo is Viatris’ Q1 2026 update, where the company reported US$3,517.0 million in revenue and returned to positive net income for the quarter while reiterating full year revenue guidance of US$14.45 billion to US$14.95 billion. For investors following catalysts, that quarter underlined gradual progress toward profitability targets, but also kept the spotlight on whether upcoming product launches can meaningfully improve earnings quality and support the dividend.

Yet against this progress, you should be aware that pricing and regulatory pressures on the core generics portfolio could still...

Viatris' narrative projects $15.5 billion revenue and $696.2 million earnings by 2029. This requires 2.0% yearly revenue growth and a $992.7 million earnings increase from -$296.5 million today.

Uncover how Viatris' forecasts yield a $17.94 fair value, in line with its current price.

Exploring Other Perspectives

Before this approval, the most pessimistic analysts were modeling only about 1.8% annual revenue growth and US$469.0 million of earnings by 2029, so compared with a more optimistic view that Viatris’ higher margin launches could steadily offset generics pressure, their narrative is far more cautious and shows how differently you might weigh Gwyn Lo’s potential impact.

Explore 7 other fair value estimates on Viatris - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.